General Information of Drug (ID: DMTROIQ)

Drug Name
PMID25991433-Compound-O2 Drug Info
Cross-matching ID
TTD Drug ID
DMTROIQ

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Patented Agent(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ozagrel DMIGKA1 Xerophthalmia 5B55.Y Phase 4 [2]
Losmapimod DMIL37Z Acute coronary syndrome BA41 Phase 3 [2]
VX-702 DMKJDR6 Coronary artery disease BA80 Phase 2a [3]
VX-745 DMJAEG6 Alzheimer disease 8A20 Phase 2 [4]
Dilmapimod DMBYJ92 Acute lung injury NB32.3 Phase 2 [2]
PMID25991433-Compound-A1 DM89LF0 N. A. N. A. Patented [1]
PMID25991433-Compound-F2 DM37VIQ N. A. N. A. Patented [1]
PMID25991433-Compound-L2 DM58UO9 N. A. N. A. Patented [1]
PMID25991433-Compound-L3 DM3LWUR N. A. N. A. Patented [1]
PMID25991433-Compound-L1 DM2135Y N. A. N. A. Patented [1]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Stress-activated protein kinase 2a (p38 alpha) TTQBR95 MK14_HUMAN Inhibitor [1]

References

1 c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
2 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
3 Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies. Arthritis Rheum. 2009 May;60(5):1232-41.
4 Pharmacological inhibitors of MAPK pathways. Trends Pharmacol Sci. 2002 Jan;23(1):40-5.